Literature DB >> 8825865

Loss of tumorigenicity and increased immunogenicity induced by interleukin-10 gene transfer in B16 melanoma cells.

C M Gérard1, C Bruyns, A Delvaux, N Baudson, J L Dargent, M Goldman, T Velu.   

Abstract

Because interleukin-10 (IL-10) has potent immunosuppressive and anti-inflammatory properties and is produced by some cancers, we hypothesized that its production might play a role in carcinogenesis by inhibiting adequate antitumoral immune responses. To test this hypothesis, retroviral vectors containing the IL-10 cDNA were generated and used to infect B16F1 melanoma cells that were injected subcutaneously in syngeneic mice. Surprisingly, IL-10 gene transfer resulted in a loss of tumorigenicity that was proportional to the amount of IL-10 secreted. Histological analysis showed massive area of necrosis of these tumor cells, with infiltration of polymorphic inflammatory cells. Parental cells simultaneously implanted had decreased tumorigenicity only when mixed with IL10-producing cells, but not when injected contralaterally, suggesting that their eradication is mediated mostly by a local phenomenon. Host T lymphocytes and natural killer (NK) cells were involved in this eradication because IL-10-producing cells grew in nude mice and in CD8+ or NK-depleted mice. Finally, mice injected with IL-10-secreting cells developed an antitumoral systemic immune response able to protect them against a subsequent challenge with parental cells. These results demonstrate that, in some settings, IL10 may have in vivo immunostimulating and proinflammatory properties that need to be considered in its therapeutic development.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8825865     DOI: 10.1089/hum.1996.7.1-23

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN: 1043-0342            Impact factor:   5.695


  12 in total

Review 1.  Immunotherapy III: Combinatorial molecular immunotherapy--a synthesis and suggestions.

Authors:  R G Vile; H Chong
Journal:  Cancer Metastasis Rev       Date:  1996-09       Impact factor: 9.264

2.  IFN-gamma and IL-12 but not IL-10 are required for local tumour surveillance in a syngeneic model of orthotopic bladder cancer.

Authors:  J Riemensberger; A Böhle; S Brandau
Journal:  Clin Exp Immunol       Date:  2002-01       Impact factor: 4.330

3.  Human glioma cells transformed by IGF-I triple helix technology show immune and apoptotic characteristics determining cell selection for gene therapy of glioblastoma.

Authors:  A Ly; H T Duc; M Kalamarides; L A Trojan; Y Pan; A Shevelev; J C François; T Noël; A Kane; D Henin; D D Anthony; J Trojan
Journal:  Mol Pathol       Date:  2001-08

4.  IL-10 enhances CTL-mediated tumor rejection by inhibiting highly suppressive CD4+ T cells and promoting CTL persistence in a murine model of plasmacytoma.

Authors:  Lixin Wang; Jin-Qing Liu; Fatemeh Talebian; Zhenzhen Liu; Li Yu; Xue-Feng Bai
Journal:  Oncoimmunology       Date:  2015-05-13       Impact factor: 8.110

Review 5.  Interleukin 10 in the tumor microenvironment: a target for anticancer immunotherapy.

Authors:  Takami Sato; Mizue Terai; Yutaka Tamura; Vitali Alexeev; Michael J Mastrangelo; Senthamil R Selvan
Journal:  Immunol Res       Date:  2011-12       Impact factor: 2.829

6.  Interleukin-10 promotes B16-melanoma growth by inhibition of macrophage functions and induction of tumour and vascular cell proliferation.

Authors:  M L García-Hernández; R Hernández-Pando; P Gariglio; Jaime Berumen
Journal:  Immunology       Date:  2002-02       Impact factor: 7.397

7.  Loss of tissue expression of interleukin-10 promotes the disease progression of colorectal carcinoma.

Authors:  Yuji Toiyama; Chikao Miki; Yasuhiro Inoue; Sayaka Minobe; Hiroko Urano; Masato Kusunoki
Journal:  Surg Today       Date:  2009-12-29       Impact factor: 2.549

8.  EBAG9 modulates host immune defense against tumor formation and metastasis by regulating cytotoxic activity of T lymphocytes.

Authors:  T Miyazaki; K Ikeda; K Horie-Inoue; T Kondo; S Takahashi; S Inoue
Journal:  Oncogenesis       Date:  2014-11-03       Impact factor: 7.485

9.  Regulation of adaptive immunity; the role of interleukin-10.

Authors:  T H Sky Ng; Graham J Britton; Elaine V Hill; Johan Verhagen; Bronwen R Burton; David C Wraith
Journal:  Front Immunol       Date:  2013-05-31       Impact factor: 7.561

10.  IL-10Rα expression is post-transcriptionally regulated by miR-15a, miR-185, and miR-211 in melanoma.

Authors:  Isabella Venza; Maria Visalli; Concetta Beninati; Salvatore Benfatto; Diana Teti; Mario Venza
Journal:  BMC Med Genomics       Date:  2015-12-03       Impact factor: 3.063

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.